N-[(2-chloro-4-fluorophenyl)methyl]-N-[(4-phenylphenyl)methyl]benzenesulfonamide | 1221277-81-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(2-chloro-4-fluorophenyl)methyl]-N-[(4-phenylphenyl)methyl]benzenesulfonamide
• CAS: 1221277-81-1
• 化学式: C₂₆H₂₁ClFNO₂S
• 分子量: 465.976
• InChiKey: INHFGMLOZMSHPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  、 2-氯-4-氟溴苄 在 MP-carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-[(2-chloro-4-fluorophenyl)methyl]-N-[(4-phenylphenyl)methyl]benzenesulfonamide
  参考文献：
  名称：

  Discovery of Tertiary Sulfonamides as Potent Liver X Receptor Antagonists

  摘要：

  Tertiary sulfonamides were identified in a FITS as dual liver X receptor (LXR, NR1H2, and NR1H3) ligands, and the binding affinity of the series was increased through iterative analogue synthesis. A ligand-bound cocrystal structure was determined which elucidated key interactions for high binding affinity. Further characterization of the tertiary sulfonamide series led to the identification of high affinity LXR antagonists. GSK 2033 (17) is the first potent cell-active LXR antagonist described to date. 17 may be a useful chemical probe to explore the cell biology of this orphan nuclear receptor.

  DOI：

  10.1021/jm901797p

文献信息

• Discovery of Tertiary Sulfonamides as Potent Liver X Receptor Antagonists
  作者：William J. Zuercher、Richard G. Buckholz、Nino Campobasso、Jon L. Collins、Cristin M. Galardi、Robert T. Gampe、Stephen M. Hyatt、Susan L. Merrihew、John T. Moore、Jeffrey A. Oplinger、Paul R. Reid、Paul K. Spearing、Thomas B. Stanley、Eugene L. Stewart、Timothy M. Willson

  DOI：10.1021/jm901797p

  日期：2010.4.22

  Tertiary sulfonamides were identified in a FITS as dual liver X receptor (LXR, NR1H2, and NR1H3) ligands, and the binding affinity of the series was increased through iterative analogue synthesis. A ligand-bound cocrystal structure was determined which elucidated key interactions for high binding affinity. Further characterization of the tertiary sulfonamide series led to the identification of high affinity LXR antagonists. GSK 2033 (17) is the first potent cell-active LXR antagonist described to date. 17 may be a useful chemical probe to explore the cell biology of this orphan nuclear receptor.